DHEA Dosing in Adrenal Insufficiency and Other Populations
For patients with adrenal insufficiency, initiate DHEA at 25-50 mg orally once daily in the morning, with dose adjustment based on plasma DHEA levels and clinical response over 3-6 months; discontinue if no sustained benefit is observed. 1
Adrenal Insufficiency - Women
DHEA replacement should be considered specifically in women with primary or secondary adrenal insufficiency who have persistent symptoms of low libido, depressive symptoms, and/or low energy levels despite optimized glucocorticoid and mineralocorticoid replacement. 1, 2
Dosing Protocol
- Starting dose: 25-50 mg orally once daily in the morning 1, 2
- Trial duration: Initial 6-month trial period 2
- Monitoring: Measure morning serum DHEA-sulfate (DHEAS) levels before the daily dose, targeting the mid-normal range for premenopausal women 2
- Discontinuation criteria: If no sustained beneficial effect after 6 months, or if adverse effects develop, DHEA should be discontinued 1, 2
Evidence Quality and Nuances
The French consensus guidelines (2018) provide a weak recommendation with level of evidence ++ for DHEA use in adrenal insufficiency 1. The Endocrine Society guideline (2016) similarly suggests DHEA replacement with a 2QQEE recommendation strength, indicating low-quality evidence 2. This reflects the inconsistent clinical trial data showing variable benefits on quality of life, mood, and sexual function. 3, 4
A pivotal 1999 study demonstrated that 50 mg DHEA daily in women with adrenal insufficiency significantly improved overall well-being, depression, anxiety, and multiple aspects of sexuality compared to placebo 3. However, a 2009 meta-analysis found only small improvements in health-related quality of life and depression, with no consistent effects on anxiety or sexual well-being 5.
Pharmacokinetic Considerations
In young healthy women with dexamethasone-suppressed adrenal function, 50 mg DHEA restores DHEAS to baseline levels and normalizes dihydrotestosterone and estrone, while 100 mg produces supraphysiological DHEAS concentrations. 6 This supports 50 mg as the appropriate replacement dose for most women with adrenal insufficiency 6.
DHEA has an apparent terminal half-life exceeding 20 hours due to back-hydrolysis from the large DHEAS pool formed after oral administration, providing sustained unconjugated DHEA and metabolites throughout the day 7. Women demonstrate significantly greater metabolic conversion of DHEAS to DHEA compared to men, which may explain sex-specific clinical responses. 7
Adrenal Insufficiency - Men
There is insufficient evidence to recommend routine DHEA replacement in men with adrenal insufficiency. 8 The 2014 consensus statement explicitly states "there is insufficient evidence of benefit to recommend routine replacement of adrenal androgens" 8. Unlike women, men with adrenal insufficiency do not consistently demonstrate clinical benefits from DHEA supplementation in available studies 4.
Healthy Older Adults
DHEA supplementation is NOT recommended for healthy older adults, as it does not provide clinically meaningful benefits and may cause adverse effects. 9, 10
Evidence Against Use in Healthy Aging
A large randomized controlled trial (DAWN trial) in 225 healthy adults aged 55-85 years receiving 50 mg DHEA daily for one year showed:
- No reduction in central adiposity or improvement in insulin action 9
- Modest and selective benefit on lumbar spine bone mineral density in women only (p=0.03), with no effect on hip, femoral neck, or total body BMD 10
- No bone benefit for men at any skeletal site 10
- Decreased HDL-cholesterol (p=0.01) and triglycerides (p=0.02) in both sexes 9
The HDL-lowering effect is particularly concerning as it may offset any potential cardiovascular benefit from triglyceride reduction. 9 While DHEA increased testosterone, estradiol, and IGF-1 levels in women and decreased bone resorption markers, these biochemical changes did not translate into clinically significant improvements in body composition or metabolic function 10.
Critical Monitoring Parameters
For Patients on DHEA Replacement
- Morning serum DHEAS levels (before daily dose): Target mid-normal range for age and sex 1, 2
- Clinical assessment: Evaluate symptoms that prompted initiation (libido, mood, energy) 1
- Adverse effects monitoring: Watch for androgenic effects (acne, hirsutism, voice deepening in women) 2
Common Pitfalls to Avoid
- Do not use DHEA as routine replacement in all patients with adrenal insufficiency - it should be reserved for symptomatic women with specific quality of life impairments despite optimal glucocorticoid/mineralocorticoid replacement 1, 2
- Do not continue DHEA indefinitely without reassessing benefit - discontinue after 6 months if no sustained improvement 2
- Do not use DHEA in healthy individuals for "anti-aging" purposes - evidence does not support benefit and HDL reduction is concerning 9, 10
- Ensure glucocorticoid and mineralocorticoid replacement is optimized first before considering DHEA, as suboptimal primary replacement may cause symptoms mistakenly attributed to DHEA deficiency 1, 2
Special Populations
Hypopituitarism
One randomized controlled study of transdermal testosterone (300 μg/day) in 52 women with hypopituitarism for 12 months showed increased hip and radial BMD, increased muscle mass, and improvements in mood and sexual function 5. However, long-term safety remains unknown, and if DHEA is considered in this population, patients should be treated and monitored using the same approach as women with HSDD 5.
Pregnancy
There are no specific guidelines for DHEA use during pregnancy in women with adrenal insufficiency. The focus during pregnancy should be on optimizing hydrocortisone replacement, with potential dose increases particularly during the third trimester 2.